Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Hepatitis B | Research

Evaluating the impact of COVID-19 outbreak on hepatitis B and forecasting the epidemiological trend in mainland China: a causal analysis

Authors: Chao-Qun He, Bai-Hong Sun, Wang-Tao Yu, Shu-Yi An, Bao-Jun Qiao, Wei Wu

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

It is uncertain how COVID-19 outbreak influences the hepatitis B epidemics. This study aims to evaluate the effects on hepatitis B owing to the COVID-19 outbreak and forecast the hepatitis B epidemiological trend in mainland China to speed up the course of the “End viral hepatitis Strategy”.

Methods

We estimated the causal impacts and created a forecast through adopting monthly notifications of hepatitis B each year from 2005 to 2020 in mainland China using the Bayesian structural time series (BSTS) method.

Results

The hepatitis B epidemics fluctuates irregularly during the period 2005–2007(APC = 8.7, P = 0.246) and 2015–2020(APC = 1.7, P = 0.290), and there is a downturn (APC=-3.2, 95% CI -5.2 to -1.2, P = 0.006) from 2007 to 2015 in mainland China. The COVID-19 outbreak was found to have a monthly average reduction on the hepatitis B epidemics of 26% (95% CI 18–35%) within the first three months in 2020,17% (95% CI 7.7–26%) within the first six months in 2020, and 10% (95% CI19–22%) all year as a result of the COVID-19 outbreak, (probability of causal effect = 96.591%, P = 0.034) and the forecasts showed an upward trend from 2021 to 2025 (annual percentage change = 4.18, 95% CI 4.0 to 4.3, P < 0.001).

Conclusion

The COVID-19 has a positive effect on the decline of hepatitis B cases. And the potential of BSTS model to forecast the epidemiological trend of the hepatitis B can be applied in automatic public health policymaking in mainland China.
Appendix
Available only for authorised users
Literature
1.
2.
Khan T, Jung IH, Khan A, Zaman G. Classification and sensitivity analysis of the transmission dynamic of Hepatitis B. Theor Biol Med Model. 2017;14(1):22.CrossRefPubMedPubMedCentral
3.
Kammerlander R, Zimmermann H. [Transmission of Hepatitis B]. Soz Praventivmed. 1998;43(Suppl 1):31–3.CrossRef
4.
Lok AS, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B: 2000–summary of a workshop. Gastroenterology. 2001;120(7):1828–53.CrossRefPubMed
5.
Liang TJ. Hepatitis B: the virus and Disease. Hepatology (Baltimore MD). 2009;49(5 Suppl):13–21.CrossRef
6.
Lok AS. Hepatitis: long-term therapy of chronic Hepatitis B reverses Cirrhosis. Nat Reviews Gastroenterol Hepatol. 2013;10(4):199–200.CrossRef
7.
Wang P, Zhang L, He J, Zhang G, Ma Y, Lv W, Zhang X, An J. Accuracy of Hepatitis B Disease surveillance, Gannan prefecture, Gansu Province, China; 2017. PLoS ONE. 2022;17(9):e0274798.CrossRefPubMedPubMedCentral
8.
Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, Ji F, Yuen MF, Zhuang G, Seto WK, et al. Cost-effectiveness of universal screening for chronic Hepatitis B virus Infection in China: an economic evaluation. The Lancet Global Health. 2022;10(2):e278–87.CrossRefPubMedPubMedCentral
9.
10.
Chen S, Mao W, Guo L, Zhang J, Tang S. Combating Hepatitis B and C by 2030: achievements, gaps, and options for actions in China. BMJ Global Health 2020, 5(6).
11.
12.
Mallah SI, Ghorab OK, Al-Salmi S, Abdellatif OS, Tharmaratnam T, Iskandar MA, Sefen JAN, Sidhu P, Atallah B, El-Lababidi R, et al. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 2021;20(1):35.CrossRefPubMedPubMedCentral
13.
Shivalkar S, Pingali MS, Verma A, Singh A, Singh V, Paital B, Das D, Varadwaj PK, Samanta SK. Outbreak of COVID-19: a detailed overview and its consequences. Adv Exp Med Biol. 2021;1353:23–45.CrossRefPubMed
14.
15.
16.
17.
Liu Q, Li Z, Ji Y, Martinez L, Zia UH, Javaid A, Lu W, Wang J. Forecasting the seasonality and trend of pulmonary Tuberculosis in Jiangsu Province of China using advanced statistical time-series analyses. Infect drug Resist. 2019;12:2311–22.CrossRefPubMedPubMedCentral
18.
Feroze N. Forecasting the patterns of COVID-19 and causal impacts of lockdown in top five affected countries using Bayesian Structural Time Series Models. Chaos, solitons, and fractals 2020, 140:110196.
19.
Vavilala H, Yaladanda N, Krishna Kondeti P, Rafiq U, Mopuri R, Gouda KC, Rao Bhimala K, Rao Kadiri M, Upadhyayula SM, Rao Mutheneni S. Weather integrated Malaria prediction system using bayesian structural time series model for northeast states of India. Environ Sci Pollut Res Int. 2022;29(45):68232–46.CrossRefPubMed
20.
Ishwaran H, Rao JS. Spike and slab variable selection: Frequentist and bayesian strategies. Ann Stat. 2005;33(2):730–73.CrossRef
21.
Varian H, Acm. Predicting the Present with Search Engine Data. In: 19th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD): Aug 11–14 2013; Chicago, IL; 2013: 4–4.
22.
Lu Z, Lou W. Bayesian approaches to variable selection: a comparative study from practical perspectives. Int J Biostatistics. 2021;18(1):83–108.CrossRef
23.
Jun S. Bayesian structural Time Series and Regression modeling for sustainable Technology Management. Sustainability 2019, 11(18).
24.
Gallego V, Suarez-Garcia P, Angulo P, Gomez-Ullate D. Assessing the effect of advertising expenditures upon sales: a bayesian structural time series model. Appl Stoch Models Bus Ind. 2019;35(3):479–91.CrossRef
25.
Ezabadi SG, Amini P, Almasi-Hashiani A, Sahraian MA, Najafi M, Eskandarieh S. Bayesian structural time series of multiple sclerosis projection in Tehran, Iran. Multiple Scler J. 2021;27(2SUPPL):232–2.
26.
Takyi PO, Bentum-Ennin I. The impact of COVID-19 on stock market performance in Africa: a bayesian structural time series approach. J Econ Bus. 2021;115:105968.CrossRefPubMed
27.
Chang SM, Chen RB, Chi YC. Bayesian variable selections for Probit models with Componentwise Gibbs Samplers. Commun Statistics-Simulation Comput. 2016;45(8):2752–66.CrossRef
28.
Fisman D. Seasonality of viral Infections: mechanisms and unknowns. Clin Microbiol Infection: Official Publication Eur Soc Clin Microbiol Infect Dis. 2012;18(10):946–54.CrossRef
29.
30.
Tian H, Liu Y, Li Y, Wu CH, Chen B, Kraemer MUG, Li B, Cai J, Xu B, Yang Q, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Sci (New York NY). 2020;368(6491):638–42.CrossRef
31.
Sagnelli C, Pisaturo M, Curatolo C, Codella AV, Coppola N, Sagnelli E. Hepatitis B virus/hepatitis D virus epidemiology: changes over time and possible future influence of the SARS-CoV-2 pandemic. World J Gastroenterol. 2021;27(42):7271–84.CrossRefPubMedPubMedCentral
32.
Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P. SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. Heart Lung Circ. 2020;29(7):973–87.CrossRefPubMedPubMedCentral
33.
Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genom. 2020;52(11):549–57.CrossRef
34.
Norton A, Mphahlele J, Yazdanpanah Y, Piot P, Bayona MT. Strengthening the global effort on COVID-19 research. Lancet (London England). 2020;396(10248):375.CrossRefPubMed
35.
Cucunubá ZM. Latin American scientific research prorities for COVID-19 prevention and control. Biomedica: revista del Instituto Nacional De Salud. 2020;40(Supl 2):9–13.CrossRefPubMed
36.
Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ. Current status of Epidemiology, diagnosis, therapeutics, and vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313–24.CrossRefPubMedPubMedCentral
37.
Andriamandimby SF, Olive MM, Shimakawa Y, Rakotomanana F, Razanajatovo IM, Andrianinarivomanana TM, Ravalohery JP, Andriamamonjy S, Rogier C, Héraud JM. Prevalence of chronic Hepatitis B virus Infection and infrastructure for its diagnosis in Madagascar: implication for the WHO’s elimination strategy. BMC Public Health. 2017;17(1):636.CrossRefPubMedPubMedCentral
38.
Brodersen KH, Gallusser F, Koehler J, Remy N, Scott S. Inferring causal impact using bayesian structural time-series models. The Annals of Applied Statistics. 2015;9:247–74.CrossRef
39.
Brodersen KH, Gallusser F, Koehler J, Remy N, Scott SL. INFERRING CAUSAL IMPACT USING BAYESIAN STRUCTURAL TIME-SERIES MODELS. Annals of Applied Statistics. 2015;9(1):247–74.CrossRef
40.
Zhao X, Shi X, Lv M, Yuan B, Wu J. Prevalence and factors associated with Hepatitis B virus Infection among household members: a cross-sectional study in Beijing. Hum Vaccines Immunotherapeutics. 2021;17(6):1818–24.CrossRef
41.
42.
Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic Infections. Proc Natl Acad Sci USA. 2020;117(48):30547–53.CrossRefPubMedPubMedCentral
43.
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject Drugs: a multistage systematic review. The Lancet Global Health. 2017;5(12):e1192–207.CrossRefPubMedPubMedCentral
44.
Wang Y, Xu C, Zhang S, Wang Z, Yang L, Zhu Y, Yuan J. Temporal trends analysis of Tuberculosis morbidity in mainland China from 1997 to 2025 using a new SARIMA-NARNNX hybrid model. BMJ open. 2019;9(7):e024409.CrossRefPubMedPubMedCentral
45.
Madhavan M, Ali Sharafuddin M, Piboonrungroj P, Yang C-C. Short-term forecasting for Airline Industry: the case of. Indian Air Passenger and Air Cargo 0(0):0972150920923316.
46.
Liao X, Liang Z. Strategy vaccination against Hepatitis B in China. Hum Vaccines Immunotherapeutics. 2015;11(6):1534–9.
Metadata
Title
Evaluating the impact of COVID-19 outbreak on hepatitis B and forecasting the epidemiological trend in mainland China: a causal analysis
Authors
Chao-Qun He
Bai-Hong Sun
Wang-Tao Yu
Shu-Yi An
Bao-Jun Qiao
Wei Wu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-023-17587-3

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue

Research

Using online search activity for earlier detection of gynaecological malignancy

Research

Predictors associated with an increase in daily steps among people with prediabetes or type 2 diabetes participating in a two-year pedometer intervention

Research

The association between health-related quality of life and problem gambling severity: a cross-sectional analysis of the Health Survey for England

Research

Significant insights from a National survey in China: PrEP awareness, willingness, uptake, and adherence among YMSM students

Research

Cohort profile: China undergraduate cohort for environmental health study

Research

Correlation of geopolitics, education, democracy with COVID-19 vaccination rate